There were 1,725 press releases posted in the last 24 hours and 439,317 in the last 365 days.

Autolus Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference

LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the Cowen and Company 39th Annual Healthcare Conference in Boston, on March 11, at 2:10 pm ET.

A live webcast of the presentation will be available on the investor relations section of the company's website: https://www.autolus.com. An archived replay will be available on the company’s website for a period of 90 days after the conference.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: https://www.autolus.com

Investor contact:                             
S.A. Noonan Communications
Susan A. Noonan
+1-212-966-3650
susan@sanoonan.com 
International Media Contact:
JW Communications 
Julia Wilson
+44 (0) 7818 430877
juliawilsonuk@gmail.com
U.S. Media Contact:
Autolus Therapeutics plc
Silvia Taylor
+1-240-801-3850
s.taylor@autolus.com 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.